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1. Introduction 
There is now considerable evidence to indicate 
that dopamine has an inhibitory role in the control of 
TSH secretion in man [ 11. Studies with the dopamine 
antagonist domperidone [2-41, which does not cross 
the blood brain barrier [5] suggest hat this dopamin- 
ergic control is exerted at the level of the anterior 
pituitary or median eminence [6,7]. 
This report describes an investigation of the effects 
of dopamine on the secretion of TSH by isolated rat 
pituitary cells. Our studies demonstrate that dopamine 
can inhibit TSH secretion directly and suggest hat 
this type of interaction could be involved in the con- 
trol of TSH secretion in vivo. 
2. Methods 
Rat pituitary cells were isolated by minor modifi- 
cations the methods in [g-lo]. Adult male Porton- 
Wistar rats (180-220 g) were used throughout and 
the anterior pituitary glands were removed into 20 ml 
of Ca2+- and Mg2+-free Earles salts (Gibco) (at 4’C) 
and supplemented with 100 U penicillin, 100 mcg 
streptomycin and 0.25 mcg Fungizone. The glands 
were washed 4 times in this solution before being cut 
into small pieces and dispersed in 5 ml of 3% bovine 
serum albumin (BSA fraction V, Sigma), 0.4% col- 
lagenase (type I, Sigma), 0.2% Dispase II (Boerhinger, 
Mannheim), 0.1% hyaluronidase (Type S, Sigma), 
0.0 1% deoxyribonuclease (DNase I, Sigma), in 137 
mM NaCl; 5 mM KCl; 0.7 mM Na2HP04; 10 mM 
glucose; 2.5 mM Hepes for 75-90 min at 37’C. 
Further dispersion was achieved by gentle repeated 
suction through a siliconised Pasteur pipette. 
The cells were washed 3 times in alpha-modified 
minimum essential medium (ar-MEM, Flow) supple- 
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mented with antibiotics (as above), 10% fetal calf 
serum (Gibco) and 1 mM glutamine, resuspended in 
the same medium and seeded in 1 ml aliquots (0.25- 
0.5 X lo6 cells/ml) into multiwell plates (Falcop 
3008). 
The cells were then cultured in an atmosphere of 
water-saturated 95% air, 5% C02, at 37°C and at 2 
days the cultures were adjusted to 0.5 mM in dibuty- 
ryl CAMP (Sigma). 
Experiments were performed on the third day of 
culture, the medium being replaced with (Y-MEM 
alone and the appropriate test material added in 20 
1.11 aliquots 6-10 wells/test point. Significance was 
determined by Student’s t-test. The cells were incu- 
bated for 3 h at 37°C after which time the medium 
was removed, diluted with an equal volume of BSA 
(1% in 0.01 M P04; 0.15 M NaCl; 0.01% merthiolate), 
stored at -2O’C and then assayed for TSH and pro- 
lactin using radioimmunoassay materials kindly pro- 
vided by Dr A. F. Parlow of the National Pituitary 
Agency. TSH measurements were expressed as ng 
NIAMD-rat TSH-RP-1. 
3. Results 
Thyrotrophin releasing hormone (TRH; Roche) 
at 10-‘“-10-7 M stimulated TSH secretion by the 
pituitary cells in a dose-dependant manner. For stu- 
dies on the effects of dopamine on TRH-stimulated 
TSH secretion a concentration of TRH (5 X lo-* M) 
that gave submaximal stimulation was used. Similarly 
a submaximal concentration (5 X lOa M) of dibuty- 
ryl cyclic AMP (DBC, Sigma) was also used in studies 
of the effects of dopamine on DBC-stimulated TSH 
secretion. 
Dopamine was found to inhibit secretion of TSH 
by both TRH stimulated and non-stimulated cells. 
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Fig.1. Direct inhibition of TSH secretion by dopamine. 
The effect was dose-dependant over 1O-7-1O-s M 
with significant inhibition (P < 0.01) of secretion 
occuring at 10 4 M (fig.1). In con trast to its effects 
on non-stimulated and TSH-stimulated cells, dopamine 
did not significantly inhibit TSH secretion by DBC- 
stimulated cells (fig.1). 
TSH secretion by non-stimulated pituitary cells 
could also be inhibited in a dose-dependant manner 
by the dopamine agonist bromocryptine (Sandoz) 
(fig.2). The effect was significant at a drug level of 
7 X lo-” M (P< 0.01). 
The influence of dopamine and bromocryptine on 
TRH-stimulated and unstimulated prolactm release 
by the cultures was also determined in each experi- 
ment. The effects on prolactin secretion were found 
to parallel those on TSH secretion however prolactin 
secretion was inhibited by lower (-lo-fold) concen- 
trations of dopamine and bromocryptine (not shown). 
The effect of dopamine on TSH secretion by TRH- 
stimulated cells could be inhibited in a dose-dependant 
manner by the dopamine antagonists metoclopramide 
(Berke) and domperidone (Janssen) (fig.3). The effect 
of metoclopramide was significant (P < 0.01) at lo-” 
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Fig.2. Inhibition of TSH secretion by the dopaminergic 
agonist bromocryptine. 
M and domperidone at 10m8 M (Z’< 0.01). Metoclopr- 
amide and domperidone inhibited the effect of dop- 
amine on TRH-stimulated prolactin secretion in a 
similar manner however the effects of these agents 
on dopamine inhibition of prolactin release were 
observed at an -lo-fold lower drug concentration 
(not shown). 
soo- 
hktoclaprom~de 
“g TSH 
secreted 400- 
(mean + SEMI 
_\v 
I 
300- Domperldone 
addltlons 
to cells 
Dopmvne ontagonlst 
Concentration (M) 
101’ IO”0 h-9 10-a 
Fig.3. Effect of dopamine antagonists on dopaminergic 
inhibition of TSH secretion. 
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4. Discussion References 
These studies demonstrate that dopamine can 
inhibit TSH secretion by isolated pituitary cells. 
Furthermore the effects of dopamine can be mimicked 
by a dopamine agonist and inhibited by dopamine 
antagonists. This provides direct evidence that TSH 
secretion can be controlled by dopaminergic mecha- 
nisms at the level of the thyrotroph. 
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